BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32129012)

  • 1. Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles.
    Nuñez-Peralta C; Alonso-Pérez J; Llauger J; Segovia S; Montesinos P; Belmonte I; Pedrosa I; Montiel E; Alonso-Jiménez A; Sánchez-González J; Martínez-Noguera A; Illa I; Díaz-Manera J
    J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):1032-1046. PubMed ID: 32129012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT.
    Fernández-Simón E; Carrasco-Rozas A; Gallardo E; González-Quereda L; Alonso-Pérez J; Belmonte I; Pedrosa-Hernández I; Montiel E; Segovia S; Suárez-Calvet X; Llauger J; Mayos M; Illa I; Barba-Romero MA; Barcena J; Paradas C; Carzorla MR; Creus C; Coll-Cantí J; Díaz M; Domínguez C; Fernández-Torrón R; García-Antelo MJ; Grau JM; López de Munáin A; Martínez-García FA; Morgado Y; Moreno A; Morís G; Muñoz-Blanco MA; Nascimento A; Parajuá-Pozo JL; Querol L; Rojas R; Robledo-Strauss A; Rojas-Marcos Í; Salazar JA; Usón M; Díaz-Manera J
    Mol Genet Metab; 2019; 128(1-2):129-136. PubMed ID: 31378569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal muscle magnetic resonance imaging in Pompe disease.
    Díaz-Manera J; Walter G; Straub V
    Muscle Nerve; 2021 May; 63(5):640-650. PubMed ID: 33155691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study.
    Figueroa-Bonaparte S; Llauger J; Segovia S; Belmonte I; Pedrosa I; Montiel E; Montesinos P; Sánchez-González J; Alonso-Jiménez A; Gallardo E; Illa I; ; Díaz-Manera J
    Sci Rep; 2018 Jul; 8(1):10898. PubMed ID: 30022036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy.
    Lollert A; Stihl C; Hötker AM; Mengel E; König J; Laudemann K; Gökce S; Düber C; Staatz G
    PLoS One; 2018; 13(1):e0190784. PubMed ID: 29315315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion tensor imaging reveals changes in non-fat infiltrated muscles in late onset Pompe disease.
    Rehmann R; Froeling M; Rohm M; Forsting J; Kley RA; Schmidt-Wilcke T; Karabul N; Meyer-Frießem CH; Vollert J; Tegenthoff M; Vorgerd M; Schlaffke L
    Muscle Nerve; 2020 Oct; 62(4):541-549. PubMed ID: 32654203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation Between Respiratory Accessory Muscles and Diaphragm Pillars MRI and Pulmonary Function Test in Late-Onset Pompe Disease Patients.
    Reyes-Leiva D; Alonso-Pérez J; Mayos M; Nuñez-Peralta C; Llauger J; Belmonte I; Pedrosa-Hernández I; Segovia S; Díaz-Manera J
    Front Neurol; 2021; 12():621257. PubMed ID: 33732206
    [No Abstract]   [Full Text] [Related]  

  • 8. Whole-body magnetic resonance imaging in late-onset Pompe disease: Clinical utility and correlation with functional measures.
    Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
    J Inherit Metab Dis; 2020 May; 43(3):549-557. PubMed ID: 31710733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
    Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
    Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function.
    Figueroa-Bonaparte S; Segovia S; Llauger J; Belmonte I; Pedrosa I; Alejaldre A; Mayos M; Suárez-Cuartín G; Gallardo E; Illa I; Díaz-Manera J;
    PLoS One; 2016; 11(10):e0163493. PubMed ID: 27711114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Function, structure and quality of striated muscles in the lower extremities in patients with late onset Pompe Disease-an MRI study.
    Vaeggemose M; Mencagli RA; Hansen JS; Dräger B; Ringgaard S; Vissing J; Andersen H
    PeerJ; 2021; 9():e10928. PubMed ID: 33996274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetization Transfer Ratio in Lower Limbs of Late Onset Pompe Patients Correlates With Intramuscular Fat Fraction and Muscle Function Tests.
    Nuñez-Peralta C; Montesinos P; Alonso-Jiménez A; Alonso-Pérez J; Reyes-Leiva D; Sánchez-González J; Llauger-Roselló J; Segovia S; Belmonte I; Pedrosa I; Martínez-Noguera A; Matellini-Mosca B; Walter G; Díaz-Manera J
    Front Neurol; 2021; 12():634766. PubMed ID: 33796064
    [No Abstract]   [Full Text] [Related]  

  • 15. 2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease.
    Plöckinger U; Prasad V; Ziagaki A; Tiling N; Poellinger A
    Hum Genomics; 2018 Mar; 12(1):14. PubMed ID: 29523196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study.
    Peng SS; Hwu WL; Lee NC; Tsai FJ; Tsai WH; Chien YH
    Orphanet J Rare Dis; 2016 May; 11(1):63. PubMed ID: 27183828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study.
    Wenninger S; Greckl E; Babačić H; Stahl K; Schoser B
    J Neurol; 2019 Jan; 266(1):133-147. PubMed ID: 30430231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
    Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
    Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscle diffusion MRI reveals autophagic buildup in a mouse model for Pompe disease.
    Rohm M; Russo G; Helluy X; Froeling M; Umathum V; Südkamp N; Manahan-Vaughan D; Rehmann R; Forsting J; Jacobsen F; Roos A; Shin Y; Schänzer A; Vorgerd M; Schlaffke L
    Sci Rep; 2023 Dec; 13(1):22822. PubMed ID: 38129558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newborn screening for Pompe disease in Italy: Long-term results and future challenges.
    Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB
    Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.